Financial Data and Key Metrics Changes - Total net revenue for Q4 2025 was RMB 89.1 million, a decrease of 11.7% compared to Q4 2024, primarily due to lower contributions from portfolio training programs and overseas study counseling services [10] - Gross profit for Q4 2025 was RMB 30.2 million, down from RMB 63.7 million in Q4 2024, with a gross margin of 56.4% compared to 63.1% in the prior year [10] - Total operating expenses in Q4 2025 were RMB 73.3 million, an increase from RMB 46.8 million in Q4 2024, primarily due to a one-time goodwill impairment charge of RMB 33.9 million [11] - For the full year 2025, total net revenue was RMB 268.1 million, flat compared to the prior year, with a gross profit of RMB 130.3 million, a decrease of 7.8% from RMB 141.3 million in 2024 [12][13] Business Line Data and Key Metrics Changes - The main revenue contributor in Q4 2025 was the portfolio training service, accounting for 68.8% of total net revenues, while project-based programs accounted for 74.9% of total credit hours delivered [5][10] - Revenues from research-based learning and overseas studies counseling increased by 4.6% in Q4 2025 due to more service delivery for in-school art classes [6] Market Data and Key Metrics Changes - Total student enrollment for Q4 2025 was 921, down from 1,038 in the prior year, reflecting normalized demand for services [16] - Total credit hours delivered decreased by 10.5% compared to the prior year, with project-based programs being the dominant choice [17] Company Strategy and Development Direction - The company aims to maintain its leading position in China's creative arts education industry by leveraging its skilled teaching team, high-quality offerings, and global partnerships [19] - Plans include optimizing the service portfolio, enhancing classroom utilization, expanding online course offerings, and consolidating campuses in less active markets to improve operational efficiency [20] Management's Comments on Operating Environment and Future Outlook - Management noted that overall student demand normalized in 2025 following a surge in enrollment the previous year, impacting revenues [4] - The company has a strong pipeline of research-based learning projects for Q1 2026, including the Finland Sustainable Design & Art Research Program [21] Other Important Information - The company recorded a net loss attributed to ACG of RMB 26.3 million in Q4 2025, compared to a net income of RMB 13.3 million in the prior year [12] - As of December 31, 2025, the company had RMB 85.2 million in cash and cash equivalents, total assets of RMB 408.3 million, and total liabilities of RMB 336.3 million [16] Q&A Session Summary Question: No questions were raised during the Q&A session - The operator noted that there were no questions at this time, and the call was turned back over to the CEO for closing remarks [25]

Financial Data and Key Metrics Changes - Total net revenue for Q4 2025 was RMB 89.1 million, a decrease of 11.7% compared to Q4 2024, primarily due to lower contributions from portfolio training programs and overseas study counseling services [10] - Gross profit for Q4 2025 was RMB 30.2 million, down from RMB 63.7 million in Q4 2024, with a gross margin of 56.4% compared to 63.1% in the prior year [10] - Total operating expenses in Q4 2025 were RMB 73.3 million, an increase from RMB 46.8 million in Q4 2024, primarily due to a one-time goodwill impairment charge of RMB 33.9 million [11] - For the full year 2025, total net revenue was RMB 268.1 million, flat compared to the prior year, with a gross profit of RMB 130.3 million, a decrease of 7.8% from RMB 141.3 million in 2024 [12][13] Business Line Data and Key Metrics Changes - The main revenue contributor in Q4 2025 was the portfolio training service, accounting for 68.8% of total net revenues, while project-based programs accounted for 74.9% of total credit hours delivered [5][10] - Revenues from research-based learning and overseas studies counseling increased by 4.6% in Q4 2025 due to more service delivery for in-school art classes [6] Market Data and Key Metrics Changes - Total student enrollment for Q4 2025 was 921, down from 1,038 in the prior year period, reflecting normalized demand for services [16] - Total credit hours delivered decreased by 10.5% compared to the prior year period [17] Company Strategy and Development Direction - The company aims to maintain its leading position in China's creative arts education industry by leveraging its skilled teaching team, high-quality offerings, and global partnerships [18] - Plans include optimizing the service portfolio, enhancing classroom utilization, expanding online course offerings, and consolidating campuses in less active markets to improve operational efficiency [19] Management's Comments on Operating Environment and Future Outlook - Management noted that overall student demand normalized in 2025 following a surge in enrollment the previous year, impacting revenues [4] - A strong pipeline of research-based learning projects is anticipated for Q1 2026, including the Finland Sustainable Design & Art Research Program [20] Other Important Information - The company recorded a net loss attributed to ACG of RMB 26.3 million in Q4 2025, compared to a net income of RMB 13.3 million in the prior year [12] - As of December 31, 2025, the company had RMB 85.2 million in cash and cash equivalents, total assets of RMB 408.3 million, and total liabilities of RMB 336.3 million [16] Q&A Session Summary Question: No questions were raised during the Q&A session - There were no questions from participants during the call [23]

Financial Data and Key Metrics Changes - Total net revenue for Q4 2025 was RMB 89.1 million, a decrease of 11.7% compared to Q4 2024, primarily due to lower contributions from portfolio training programs and overseas study counseling services [9] - Gross profit for Q4 2025 was RMB 30.2 million, down from RMB 63.7 million in Q4 2024, with a gross margin of 56.4% compared to 63.1% in the prior year [9] - Total operating expenses were RMB 73.3 million in Q4 2025, an increase from RMB 46.8 million in Q4 2024, primarily due to a one-time goodwill impairment charge of RMB 33.9 million [10] - For the full year 2025, total net revenue was RMB 268.1 million, flat compared to the prior year, with a gross profit of RMB 130.3 million, a decrease of 7.8% from RMB 141.3 million in 2024 [11][12] Business Line Data and Key Metrics Changes - The main revenue contributor in Q4 2025 was the portfolio training service, accounting for 68.8% of total net revenues, while project-based programs accounted for 74.9% of total credit hours delivered, up from 66.8% in Q4 2024 [5][9] - Revenues from research-based learning and overseas studies counseling increased by 4.6% in Q4 2025 due to more service delivery for in-school art classes [6] Market Data and Key Metrics Changes - Total student enrollment for Q4 2025 was 921, down from 1,038 in the prior year period, reflecting normalized demand for services [15] - Total credit hours delivered decreased by 10.5% compared to the prior year period [15] Company Strategy and Development Direction - The company aims to maintain its leading position in China's creative arts education industry by leveraging its skilled teaching team, high-quality offerings, and global partnerships [16] - Plans include optimizing the service portfolio, enhancing classroom utilization, expanding online course offerings, and consolidating campuses in less active markets to improve operational efficiency [17] - A strong pipeline of research-based learning projects is anticipated for Q1 2026, including the Finland Sustainable Design & Art Research Program [17][18] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that overall student demand normalized in 2025 following a surge in enrollment the previous year, impacting revenues [4] - The company remains focused on driving positive student outcomes and enhancing its service portfolio to cater to diverse student needs [19][20] Other Important Information - The company recorded a net loss attributed to ACG of RMB 26.3 million in Q4 2025, compared to a net income of RMB 13.3 million in the prior year [11] - As of December 31, 2025, the company had RMB 85.2 million in cash and cash equivalents, total assets of RMB 408.3 million, and total liabilities of RMB 336.3 million [15] Q&A Session Summary Question: No questions were raised during the Q&A session - There were no questions from participants during the call [22]

Core Insights - Carter's, Inc. achieved its first year-over-year revenue growth since 2021, driven by a third consecutive quarter of U.S. Retail comparable sales gains [5] - The company is transitioning to emotion-driven storytelling to build consumer loyalty and reduce reliance on heavy promotions [5] - A portfolio optimization strategy includes closing approximately 150 lower-margin stores by 2028 to improve fleet productivity [5] Financial Performance - Projected low to mid single-digit net sales growth for 2026, with performance heavily weighted toward the second half of the year [5] - Anticipating a gross tariff impact exceeding $200 million in 2026, compared to $60 million in 2025 [5] - Higher interest expenses of just under $40 million are expected in 2026 following a debt refinancing [5] Strategic Initiatives - Implementing a 20% to 30% reduction in product choices to simplify the global brand line and accelerate speed-to-market by three months [5] - Rightsizing the office-based workforce is expected to yield approximately $35 million in cost savings [5] - Phasing out the 'Simple Joys' exclusive brand on Amazon to prioritize the higher-margin Carter's namesake brand [5] Market Outlook - U.S. Wholesale is expected to return to growth in 2026 as inventory sell-through rates and future season demand signals remain strong [5] - Price coverage in the Wholesale channel is expected to improve significantly in the second half of 2026 as new contracts take effect [6]

Financial Data and Key Metrics Changes - In 2025, the company reported total revenues of $14.3 billion, representing approximately 2% growth compared to 2024, excluding the impact of the India pack [5][24] - Adjusted EBITDA for 2025 was $4.2 billion, with adjusted EPS of $2.35 per share and free cash flow of $2.2 billion, excluding transaction-related costs [24][30] - The company prioritized capital return with over $1 billion returned to shareholders through dividends and share repurchases [7][24] Business Line Data and Key Metrics Changes - The fourth quarter of 2025 saw total revenues of $3.7 billion, up 1% year-over-year, driven by strong commercial performance across key regions [23] - Growth in Greater China was supported by demand in the cardiovascular portfolio, while Europe and emerging markets benefited from the breadth and competitive strength of the portfolio [23][27] - The company expects new product revenues of $450-550 million in 2026, contributing to strong segment performance [26] Market Data and Key Metrics Changes - In developed markets, net sales are expected to grow by 2% versus 2025, with Europe anticipated to grow by 4% year-over-year [26][27] - Emerging markets are expected to grow by 6% year-over-year, driven by expansion in key growth markets such as Turkey, Mexico, India, and Brazil [27] - In Greater China, the company expects to deliver 3% year-over-year growth, primarily driven by cardiovascular products [29] Company Strategy and Development Direction - The company aims to drive its base business by executing successful launches and evolving its generics portfolio towards more profitable products [8][9] - The strategic review is expected to deliver approximately $650 million in gross cost savings over three years, with plans to reinvest up to $250 million into growth areas [7][25] - The company is focused on modernizing for sustainable growth by strengthening technology, data, and talent capabilities [9][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering a period of long-term sustainable growth beginning in 2026, with strong execution anticipated [5][10] - The company expects robust cash flow in 2026, providing financial flexibility for balanced capital allocation [11][32] - Management highlighted the importance of upcoming product launches and regulatory decisions as key drivers for future performance [10][12] Other Important Information - A fire occurred at the company's oral solid dose manufacturing facility in Nashik, India, temporarily suspending operations, with expectations to resume in April [30] - The company is preparing for regulatory decisions for several product candidates, including EFFEXOR and pitolisant in Japan, and fast-acting meloxicam in the U.S. [10][15] Q&A Session Summary Question: Path to mid-single-digit revenue growth - Management indicated that the path to mid-single-digit revenue growth involves a growing base business and upcoming product launches, with confidence in achieving this over the next few years [37][40] Question: Timing of $400 million savings from strategic review - The savings are expected to be phased over three years, with approximately 30% in 2026, 30% in 2027, and 40% in 2028 [38][42] Question: Breakdown of $650 million savings - About 50% of the savings will come from headcount reductions, with the other half from COGS efficiencies and inventory management [44][46] Question: India recovery impact on EBITDA guidance - Management assumes a little less than 1% recovery from India in the top line, with no material impact expected on 2026 guidance [44][49] Question: Restructuring charges versus net savings - The company estimates that the one-time costs necessary to achieve savings will be about 1 times the gross savings, with around $250 million expected this year [52][54] Question: Fast-acting meloxicam market focus - The initial focus for fast-acting meloxicam will be on post-operative and operative acute pain management, targeting specialty physicians [58][60] Question: Regulatory pricing challenges in Japan - Japan faces mandatory price decreases on LOE products, impacting revenue and EBITDA, but management is optimistic about future growth with new assets [62][64]

Financial Data and Key Metrics Changes - In 2025, the company reported total revenues of $14.3 billion, representing approximately 2% growth compared to 2024, excluding the impact of the India pack [4][21] - Adjusted EBITDA for 2025 was $4.2 billion, with adjusted EPS of $2.35 per share and free cash flow of $2.2 billion, excluding transaction-related costs [21][22] - For Q4 2025, total revenues were $3.7 billion, up 1% year-over-year, excluding the indoor impact [20] Business Line Data and Key Metrics Changes - The company achieved strong commercial performance across its global portfolio, with significant contributions from its cardiovascular portfolio in Greater China and competitive strength in Europe and emerging markets [20][21] - New product revenues are anticipated to contribute $450 million to $550 million in 2026, with growth expected in developed markets and emerging markets [23][24] Market Data and Key Metrics Changes - In Greater China, the company expects 3% year-over-year growth, driven primarily by cardiovascular products [25] - Emerging markets are projected to grow 6% year-over-year, supported by expansion in key markets like Turkey, Mexico, India, and Brazil [24] Company Strategy and Development Direction - The company aims to drive its base business through successful product launches and evolving its generics portfolio towards higher-margin products [6][7] - Strategic imperatives include fueling the innovative portfolio with late-stage and in-market growth assets, and modernizing operations for sustainable growth [6][7] - The company plans to deliver approximately $650 million in gross cost savings over three years, with $250 million earmarked for reinvestment in growth areas [5][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering a period of long-term sustainable growth beginning in 2026, with a focus on strong financial performance and commercial execution [4][8] - The company anticipates regulatory decisions for several product candidates in 2026, which are expected to support future performance [8][11] Other Important Information - A fire incident at the Nashik, India facility has temporarily suspended manufacturing, with operations expected to resume in April [26] - The company is focused on returning the JANZ segment to growth while managing pricing headwinds in certain Asian markets [24][25] Q&A Session Summary Question: Path to mid-single-digit revenue growth and confidence in approvals - Management indicated that the path to mid-single-digit growth involves a growing base business and upcoming product launches, with confidence in the six potential approvals this year [32][34] Question: Breakdown of $650 million savings and timing - The savings are expected to be phased over three years, with approximately 30% in 2026, 30% in 2027, and 40% in 2028 [33][38] Question: Cost cuts and India recovery assumptions - About 50% of the $650 million savings will come from headcount reductions, with less than 1% of India recovery included in the 2026 guidance [40][43] Question: Restructuring charges versus net savings - The company estimates that the one-time costs to achieve savings will be about 1 times the gross savings, with $250 million expected this year [47][49] Question: Fast-acting meloxicam market focus - The initial focus for fast-acting meloxicam will be on post-operative and operative acute pain management, targeting specialty physicians [52][54] Question: Regulatory pricing challenges in Japan - Japan faces mandatory price decreases impacting revenue and EBITDA, but new assets are expected to turn the business towards growth by 2028 [56][58]

Financial Data and Key Metrics Changes - For 2025, adjusted earnings per share (EPS) was $6.98, representing an 8.7% increase year-over-year, primarily due to higher revenue and adjusted operating income [16][17] - Adjusted gross margin for 2025 was 63.7%, a decrease of 200 basis points year-over-year, attributed to tariffs, the acquisition of Vascular Intervention, and increased logistics costs [15][16] - Adjusted operating margin for 2025 was 22.7%, reflecting a 230 basis point decrease year-over-year due to gross margin pressure and higher operating expenses [15][16] Business Line Data and Key Metrics Changes - Vascular revenue increased 2.4% year-over-year to $472.7 million, driven by growth in Central Access, hemostatic, and atomization products [14] - Interventional revenue was $427.5 million, an increase of 8.1%, supported by a broad portfolio [14] - Surgical revenue was $219.3 million, reflecting a 3.2% increase, influenced by volume-based procurement in China [14][15] Market Data and Key Metrics Changes - Continuing operations delivered 4.7% pro forma adjusted constant currency revenue growth in the second half of 2025, establishing a solid foundation for future growth [28][22] - Pro forma adjusted constant currency revenue growth for 2026 is expected to be in the range of 4.5%-5.5% [22] Company Strategy and Development Direction - The company is undergoing a transformation to optimize its portfolio and focus on high-growth areas, with plans to return significant capital to shareholders through a $1 billion share repurchase program [5][27] - The strategic divestitures of Acute Care, Interventional Urology, and OEM businesses are expected to close in the second half of 2026, with net proceeds of approximately $1.8 billion to be used for share repurchases and debt repayment [7][20] - R&D investment for RemainCo is expected to represent approximately 8% of sales, up from 5% historically, indicating a focus on product innovation [8][71] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving mid-single-digit revenue growth and significant increases in adjusted EPS in 2027 and beyond, driven by cost mitigation and capital deployment actions [30][50] - The company is actively managing stranded costs of approximately $90 million associated with the divestitures, with plans to offset these through transition service agreements and restructuring initiatives [9][24] Other Important Information - The company is currently in a CEO search process, focusing on candidates with experience in high-growth, mid-size organizations operating in global healthcare settings [51] - A restructuring plan has been approved to eliminate stranded costs and streamline operations, targeting approximately $50 million in annual pre-tax savings [24][30] Q&A Session Summary Question: Use of proceeds from divestitures - The company plans to allocate $1 billion for share repurchases and approximately $800 million for debt repayment, primarily targeting the deferred draw revolver from the Bison acquisition [33] Question: Restructuring savings impact on EPS guidance - Some restructuring savings are included in the EPS guidance range of $6.25-$6.55 for 2026, with additional savings expected post-2026 [34] Question: Confidence in revenue growth for 2026 - The company is confident in its growth trajectory due to sales synergies and easier comparisons in the second half of 2026, despite some ongoing volume-based procurement impacts [81] Question: BIOTRONIK integration update - The integration of the BIOTRONIK sales force is progressing well, with no significant talent losses and opportunities for revenue synergies identified [69][70] Question: Future margin expansion post-transition service agreements - The company aims to mitigate stranded costs and leverage operational efficiencies to improve margins, with expectations for continued growth in earnings and margins beyond 2026 [75][76]

Financial Data and Key Metrics Changes - For 2025, adjusted earnings per share (EPS) was $6.98, representing an 8.7% increase year-over-year, primarily due to higher revenue and adjusted operating income, including the impact of the Vascular Intervention acquisition [16][17] - Adjusted gross margin for 2025 was 63.7%, a decrease of 200 basis points year-over-year, attributed to tariffs, the addition of the Vascular Intervention acquisition, and increased logistics costs [15][16] - Adjusted operating margin for 2025 was 22.7%, reflecting a 230 basis point decrease due to gross margin pressure and higher operating expenses [16] Business Line Data and Key Metrics Changes - Vascular revenue increased 2.4% year-over-year to $472.7 million, driven by growth in Central Access, hemostatic, and atomization products [14] - Interventional revenue was $427.5 million, an increase of 8.1%, supported by a broad Interventional portfolio [14] - Surgical revenue was $219.3 million, reflecting a 3.2% increase, impacted by volume-based procurement in China [14] Market Data and Key Metrics Changes - Continuing operations delivered 4.7% pro forma adjusted constant currency revenue growth in the second half of 2025, establishing a solid foundation for future mid-single-digit revenue growth [22][28] - Pro forma adjusted constant currency revenue growth guidance for 2026 is expected to be in the range of 4.5%-5.5% [22] Company Strategy and Development Direction - The company is undergoing a transformation to optimize its portfolio, focusing on becoming a more streamlined medical technologies leader [27] - Strategic divestitures of the Acute Care, Interventional Urology, and OEM businesses are expected to close in the second half of 2026, with net proceeds of approximately $1.8 billion to be used for share repurchases and debt reduction [7][20][30] - R&D investment for RemainCo is expected to represent approximately 8% of sales, up from about 5% historically, indicating a focus on product innovation [8][71] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving adjusted EPS guidance for 2026 in the range of $6.25-$6.55, despite the impact of stranded costs related to divestitures [9][21] - The company anticipates significant improvements in margins and adjusted EPS in 2027 and beyond, driven by capital deployment actions and cost-saving initiatives [30][50] Other Important Information - The company is actively conducting a CEO search following the transition of leadership, focusing on candidates with experience in high-growth organizations [5][51] - A restructuring plan has been approved to mitigate approximately $50 million in stranded costs, aimed at streamlining operations and improving long-term cost structure [24][30] Q&A Session Summary Question: Use of proceeds from divestitures - The company plans to allocate $1 billion for share repurchases and approximately $800 million for debt repayment, primarily targeting the deferred draw revolver from the BIOTRONIK acquisition [33] Question: Restructuring savings impact on EPS guidance - Some restructuring savings are included in the EPS guidance for 2026, with additional savings expected post-2026 [34] Question: Confidence in revenue growth for 2026 - Confidence in revenue growth is based on anticipated sales synergies and easier comparisons in the second half of 2026, as the impact of volume-based procurement is expected to lessen [81]

Financial Data and Key Metrics Changes - In Q4 2025, Westlake reported a net loss of $33 million, or a loss of $0.25 per share, on sales of $2.5 billion, which was a $5 million lower loss compared to Q3 2025 due to lower average sales prices and sales volumes [14][15] - For the full year 2025, net loss was $116 million, with EBITDA of $1.1 billion, and total sales of $11.2 billion, reflecting an 8% decline year-over-year [15][16] - The company achieved $170 million in structural cost reductions in 2025, with an additional $60 million in Q4 alone [15][21] Business Line Data and Key Metrics Changes - The Housing and Infrastructure Products (HIP) segment experienced an 8% decline in sales year-over-year in Q4, primarily due to decreased sales volumes in PVC compounds and exterior building products, although municipal pipe sales remained strong [17][19] - The Performance and Essential Materials (PEM) segment's Q4 EBITDA was $45 million, down from $90 million in Q3, driven by a 5% decline in average sales prices and a 2% decrease in sales volume [19][20] - For the full year 2025, PEM's EBITDA was $267 million, significantly lower than in 2024 due to higher feedstock and energy costs, as well as lower global sales prices [20] Market Data and Key Metrics Changes - The company noted global overcapacity in certain products, particularly in polyethylene and core vinyls, which pressured sales prices and margins throughout 2025 [20] - The forecast for housing starts in 2026 is between 1.3 million and 1.4 million, with expectations for improved home affordability due to lower interest rates [22] Company Strategy and Development Direction - Westlake is implementing a three-pillar strategy expected to contribute $600 million in earnings improvement in 2026, focusing on footprint optimization, plant reliability, and structural cost reductions [10][12] - The company has closed several higher-cost PEM assets and is focusing on improving operational reliability to enhance profitability [11][20] - The acquisition of ACI is expected to expand product offerings and contribute positively to revenue growth in the HIP segment [22][86] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism for 2026, citing signs of improvement in global industrial and manufacturing activity and a rebound from seasonal lows [24][25] - The company aims to reduce carbon emissions intensity by 20% by 2030, having already achieved its previous emissions reduction goal six years early [25] - Management emphasized the importance of a diversified portfolio and a vertically integrated business model to navigate market challenges [25][26] Other Important Information - The Chief Financial Officer, Steve Bender, announced plans to retire later in 2026, with gratitude expressed for his contributions to the company [13][14] - Cash and securities as of December 31, 2025, were $2.9 billion, with total debt at $5.6 billion, indicating a well-positioned balance sheet [20][21] Q&A Session Summary Question: Can you break down the PEM business in Q4 and its performance? - The performance was impacted by the closure of core vinyl plants, leading to a reduction in losses and a proactive approach in cost reduction initiatives [30][32] Question: What are the expectations around polyethylene price increases? - There has been some improvement in demand and price action, with announced price increases expected to offset previous market adjustments [33][34] Question: What is the outlook for chlorovinyls and the PVC chain in 2026? - There is cautious optimism with some restocking observed, but visibility remains limited [38][39] Question: How will the $600 million in cost savings be realized throughout the year? - The savings will be realized through structural cost reductions and improved reliability, with benefits expected to accrue throughout 2026 [44][46] Question: What are the expectations for free cash flow in 2026? - The objective is to generate strong cash flows, with a focus on cost savings and improved reliability [58][60] Question: How does the company view the competitive landscape following recent changes in ownership of a competitor? - No significant changes in competition have been observed at this stage [67] Question: What is the outlook for domestic merchant chlorine? - Weakness in chlorine demand has been noted, driven by reduced demand in construction materials and water treatment [68][69] Question: How do the benefits from plant reliability and cost reduction relate to EBITDA? - The benefits will start to materialize in 2026, with a focus on cost initiatives and reduced planned outages [74][75]

Financial Data and Key Metrics Changes - In Q4 2025, the company reported a net loss of $33 million, or a loss of $0.25 per share, on sales of $2.5 billion, which was a $5 million lower loss compared to Q3 2025 [14][15] - For the full year 2025, the company reported a net loss of $116 million and EBITDA of $1.1 billion, with total sales declining 8% to $11.2 billion compared to 2024 [15][16] - The company achieved $170 million in structural cost reductions in 2025, with an additional $60 million in Q4 alone [15][21] Business Line Data and Key Metrics Changes - The Housing and Infrastructure Products (HIP) segment saw an 8% decline in sales year-over-year in Q4, primarily due to decreased sales volumes in PVC compounds and exterior building products [17][19] - The Performance and Essential Materials (PEM) segment's Q4 EBITDA was $45 million, down from $90 million in Q3, driven by a 5% decline in average sales prices and a 2% decrease in sales volume [19][20] - For the full year 2025, HIP's EBITDA was $839 million with a margin of 20%, while PEM's EBITDA was $267 million, significantly impacted by higher feedstock costs and global overcapacity [17][20] Market Data and Key Metrics Changes - The company noted a decline in new housing construction activity in North America, which negatively affected sales in the HIP segment [9][16] - Global overcapacity in certain products continued to exert downward pressure on sales prices in the PEM segment, leading to margin compression [10][20] - The company expects housing starts in 2026 to range between 1.3 million and 1.4 million, with improved home affordability due to lower interest rates [22][24] Company Strategy and Development Direction - The company is executing a three-pillar strategy aimed at achieving $600 million in earnings improvement in 2026 through footprint optimization, improved plant reliability, and additional cost reductions [10][12][21] - The company has closed several higher-cost PEM assets to reduce exposure to low-priced export markets, which is expected to yield a $100 million annual EBITDA benefit starting in 2026 [20][21] - The company remains focused on value creation and is strategically deploying its balance sheet to enhance long-term shareholder value [21][25] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding signs of improvement in global industrial and manufacturing activity, with expectations for sales volume growth in 2026 [24][26] - The company has achieved its carbon emissions reduction goal six years early and continues to prioritize sustainability and environmental stewardship [25] - Management highlighted the importance of product innovation and the recent acquisition of ACI in driving future growth in the HIP segment [22][25][86] Other Important Information - The company announced the planned retirement of its long-serving CFO, Steve Bender, later in 2026 [13][14] - The company maintains a strong balance sheet with $2.9 billion in cash and securities and total debt of $5.6 billion [20][21] Q&A Session Summary Question: Can you break down the PEM business in Q4 and its performance? - Management noted that the beat in PEM was due to proactive steps taken in their three-pillar initiative, including the removal of losses from shuttered assets and cost reduction initiatives [30][32] Question: What are the expectations around polyethylene price increases? - Management indicated some improvement in demand and price action, with announced price increases expected to offset previous market adjustments [33][34] Question: What is the outlook for chlorovinyls and PVC chain in 2026? - Management remains cautiously optimistic, noting some restocking and price improvements, but acknowledges ongoing structural supply issues [38][39] Question: How will the $600 million in cost savings be realized throughout the year? - Management explained that savings from actions taken in 2025 will continue into 2026, with expectations for structural cost reductions and improved reliability [44][46] Question: What is the expected free cash flow for 2026? - Management aims to generate strong cash flows and has reduced capital expenditures for 2026, focusing on driving free cash flow across the business [58][60] Question: How does the company view the competitive landscape and potential tariff impacts? - Management stated that the impact of tariffs has been minimal due to USMCA rules, and they do not foresee significant changes in competition from OxyChem [62][68] Question: What are the opportunities in PVC volume for 2026? - Management expects growth in domestic demand for PVC, driven by construction materials, while also noting a cautious outlook on export volumes [76][78]